Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study
Mastology · 07.04.2026 · 35
DOI: 10.29289/259453942025054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mastology, online erschienen am 07.04.2026. Verfasst von Emmanuel Filizola Cavalcante und 8 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer.
Methods
This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection.
Results
A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%.
Conclusions
Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.
Zitieren
APA
Cavalcante, E. F., Linhares, J. J., Rocha, L. G. D., Oliveira, S. C. D., Mayorga, F. D. D. O., Costa, V. O., Pinheiro, L. G. P., Chaves, F. N., & Cavalcante, D. I. M. (2026). Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study. Mastology, 35. https://doi.org/10.29289/259453942025054
Vancouver
Cavalcante EF, Linhares JJ, Rocha LGD, Oliveira SCD, Mayorga FDDO, Costa VO, et al. Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study. Mastology. 2026;35. doi:10.29289/259453942025054
BibTeX
@article{Cavalcante2026,
author = {Cavalcante, Emmanuel Filizola and Linhares, José Juvenal and Rocha, Luciana Gomes da and Oliveira, Silvando Carmo de and Mayorga, Fernando Daniel de Oliveira and Costa, Valbert Oliveira and Pinheiro, Luiz Gonzaga Porto and Chaves, Filipe Nobre and Cavalcante, Diane Isabelle Magno},
title = {Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study},
journal = {Mastology},
year = {2026},
volume = {35},
doi = {10.29289/259453942025054}
}
EUVIMED